A mechanistic study of the effect of doxorubicin/adriamycin on the estrogen response in a breast cancer model

Oncology (Switzerland)

Volumn 83, Issue 6, 2012, Pages 305-320

  Pritchard, Jessica E ^a   Dillon, Patrick M ^b   Conaway, Mark R ^a   Silva, Corinne M ^c   Parsons, Sarah J ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

^b Department of Medicine   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Breast cancer; Doxorubicin; Epidermal growth factor receptor; Estrogen; Estrogen receptor

Indexed keywords

DOXORUBICIN; ESTRADIOL;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL PROLIFERATION; CELL STRAIN MCF 7; CONTROLLED STUDY; HORMONE RESPONSE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DOXORUBICIN; DRUG INTERACTIONS; DRUG RESISTANCE, NEOPLASM; ESTRADIOL; FEMALE; HUMANS; MCF-7 CELLS; PHOSPHORYLATION; RECEPTORS, ESTROGEN; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

EID: 84865856891     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000341394     Document Type: Article

References (87)

1. NCI: SEER cancer statistics review 1975-2007. National Cancer Institute, 2011, tables 1.23-21.28.
2. Kocic B, Filipovic S, Petrovic B, Mijalkovic D, Rancic N, Poultsidi A: Clinical and biological characteristics of breast cancer. J Buon 2010; 15: 660-667.
3. Conforti R, Boulet T, Tomasic G, Taranchon E, Arriagada R, Spielmann M, Ducourtieux M, Soria JC, Tursz T, Delaloge S, Michiels S, Andre F: Breast cancer molecular subclassification and estrogen receptor expression to predict efficacy of adjuvant anthracyclinesbased chemotherapy: a biomarker study from two randomized trials. Ann Oncol 2007; 18: 1477-1483.
4. Kuerer HM, Newman LA, Smith TL, Ames FC, Hunt KK, Dhingra K, Theriault RL, Singh G, Binkley SM, Sneige N, Buchholz TA, Ross MI, McNeese MD, Buzdar AU, Hortobagyi GN, Singletary SE: Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 1999; 17: 460-469.
5. Berry DA, Cirrincione C, Henderson IC, Citron ML, Budman DR, Goldstein LJ, Martino S, Perez EA, Muss HB, Norton L, Hudis C, Winer EP: Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 2006; 295: 1658-1667.
6. Teixeira C, Reed JC, Pratt MA: Estrogen promotes chemotherapeutic drug resistance by a mechanism involving Bcl-2 proto-oncogene expression in human breast cancer cells. Cancer Res 1995; 55: 3902-3907.
7. Leung LK, Wang TT: Differential effects of chemotherapeutic agents on the Bcl-2/Bax apoptosis pathway in human breast cancer cell line MCF-7. Breast Cancer Res Treat 1999; 55: 73-83.
8. de Bruijn P, Verweij J, Loos WJ, Kolker HJ, Planting AS, Nooter K, Stoter G, Sparreboom A: Determination of doxorubicin and doxorubicinol in plasma of cancer patients by high-performance liquid chromatography. Anal Biochem 1999; 266: 216-221.
9. Benjamin RS, Riggs CE Jr, Bachur NR: Plasma pharmacokinetics of adriamycin and its metabolites in humans with normal hepatic and renal function. Cancer Res 1977; 37: 1416-1420.
10. Creasey WA, McIntosh LS, Brescia T, Odujinrin O, Aspnes GT, Murray E, Marsh JC: Clinical effects and pharmacokinetics of different dosage schedules of adriamycin. Cancer Res 1976; 36: 216-221.
11. Wurz GT, Soc L, Emshoff VD, Cadman TB, DeGregorio MW: Pharmacokinetic analysis of high-dose toremifene in combination with doxorubicin. Cancer Chemother Pharmacol 1998; 42: 363-366.
12. Rodvold KA, Rushing DA, Tewksbury DA: Doxorubicin clearance in the obese. J Clin Oncol 1988; 6: 1321-1327.
13. Hunz M, Jetter A, Warm M, Pantke E, Tuscher M, Hempel G, Jaehde U, Untch M, Kurbacher C, Fuhr U: Plasma and tissue pharmacokinetics of epirubicin and paclitaxel in patients receiving neoadjuvant chemotherapy for locally advanced primary breast cancer. Clin Pharmacol Ther 2007; 81: 659-668.
14. Saunders DE, Lawrence WD, Christensen C, Wappler NL, Ruan H, Deppe G: Paclitaxelinduced apoptosis in MCF-7 breast-cancer cells. Int J Cancer 1997; 70: 214-220.
15. Sharma G, Tyagi AK, Singh RP, Chan DC, Agarwal R: Synergistic anti-cancer effects of grape seed extract and conventional cytotoxic agent doxorubicin against human breast carcinoma cells. Breast Cancer Res Treat 2004; 85: 1-12.
16. Rusetskaya NV, Lukyanova NY, Chekhun VF: Molecular profile and cell cycle in MCF-7 and MCF-7/DOX cells exposed to conventional and liposomal forms of doxorubicin. Exp Oncol 2009; 31: 140-143.
17. Yamashita H, Takahashi S, Ito Y, Yamashita T, Ando Y, Toyama T, Sugiura H, Yoshimoto N, Kobayashi S, Fujii Y, Iwase H: Predictors of response to exemestane as primary endocrine therapy in estrogen receptor-positive breast cancer. Cancer Sci 2009; 100: 2028-2033.
18. McGlynn LM, Kirkegaard T, Edwards J, Tovey S, Cameron D, Twelves C, Bartlett JM, Cooke TG: RAS/RAF-1/MAPK pathway mediates response to tamoxifen but not chemotherapy in breast cancer patients. Clin Cancer Res 2009; 15: 1487-1495.
19. Yamashita H, Nishio M, Toyama T, Sugiura H, Kondo N, Kobayashi S, Fujii Y, Iwase H: Low phosphorylation of estrogen receptor alpha (ERalpha) serine 118 and high phosphorylation of ERalpha serine 167 improve survival in ER-positive breast cancer. Endocr Relat Cancer 2008; 15: 755-763.
20. Critchley HO, Saunders PT: Hormone receptor dynamics in a receptive human endometrium. Reprod Sci 2009; 16: 191-199.
21. Ropero AB, Alonso-Magdalena P, Quesada I, Nadal A: The role of estrogen receptors in the control of energy and glucose homeostasis. Steroids 2008; 73: 874-879.
22. Belcher SM: Rapid signaling mechanisms of estrogens in the developing cerebellum. Brain Res Rev 2008; 57: 481-492.
23. Alvaro D, Mancino MG, Onori P, Franchitto A, Alpini G, Francis H, Glaser S, Gaudio E: Estrogens and the pathophysiology of the biliary tree. World J Gastroenterol 2006; 12: 3537-3545.
24. Khosla S: Update on estrogens and the skeleton. J Clin Endocrinol Metab 2010; 95: 3569-3577.
25. Welboren WJ, Sweep FC, Span PN, Stunnenberg HG: Genomic actions of estrogen receptor alpha: what are the targets and how are they regulated? Endocr Relat Cancer 2009; 16: 1073-1089.
26. McDevitt MA, Glidewell-Kenney C, Jimenez MA, Ahearn PC, Weiss J, Jameson JL, Levine JE: New insights into the classical and nonclassical actions of estrogen: evidence from estrogen receptor knock-out and knock-in mice. Mol Cell Endocrinol 2008; 290: 24-30.
27. Fox EM, Andrade J, Shupnik MA: Novel actions of estrogen to promote proliferation: integration of cytoplasmic and nuclear pathways. Steroids 2009; 74: 622-627.
28. Lannigan DA: Estrogen receptor phosphorylation. Steroids 2003; 68: 1-9.
29. Wong CW, McNally C, Nickbarg E, Komm BS, Cheskis BJ: Estrogen receptor-interacting protein that modulates its nongenomic activity-crosstalk with Src/Erk phosphorylation cascade. Proc Natl Acad Sci USA 2002; 99: 14783-14788.
30. Cheskis BJ, Greger J, Cooch N, McNally C, McLarney S, Lam HS, Rutledge S, Mekonnen B, Hauze D, Nagpal S, Freedman LP: MNAR plays an important role in ERa activation of Src/MAPK and PI3K/Akt signaling pathways. Steroids 2008; 73: 901-905.
31. Chieffi P, Kisslinger A, Sinisi AA, Abbondanza C, Tramontano D: 17beta-estradiolinduced activation of ERK1/2 through endogenous androgen receptor-estradiol receptor alpha-Src complex in human prostate cells. Int J Oncol 2003; 23: 797-801.
32. Thomas SM, Brugge JS: Cellular functions regulated by Src family kinases. Annu Rev Cell Dev Biol 1997; 13: 513-609.
33. Lonning PE, Haynes BP, Straume AH, Dunbier A, Helle H, Knappskog S, Dowsett M: Recent data on intratumor estrogens in breast cancer. Steroids 2011;76:786-791.
34. Barranco SC: Cellular and molecular effects of adriamycin on dividing and nondividing cells. Pharmacol Ther 1984; 24: 303-319.
35. Migliaccio A, Varricchio L, De Falco A, Castoria G, Arra C, Yamaguchi H, Ciociola A, Lombardi M, Di Stasio R, Barbieri A, Baldi A, Barone MV, Appella E, Auricchio F: Inhibition of the Sh3 domain-mediated binding of Src to the androgen receptor and its effect on tumor growth. Oncogene 2007; 26: 6619-6629.
36. Yun C, Lee JH, Park H, Jin YM, Park S, Park K, Cho H: Chemotherapeutic drug, adriamycin, restores the function of p53 protein in hepatitis B virus X (HBx) protein-expressing liver cells. Oncogene 2000; 19: 5163-5172.
37. Castoria G, Migliaccio A, Bilancio A, Di Domenico M, de Falco A, Lombardi M, Fiorentino R, Varricchio L, Barone MV, Auricchio F: PI3-kinase in concert with Src promotes the S-phase entry of oestradiol-stimulated MCF-7 cells. Embo J 2001; 20: 6050-6059.
38. Lobenhofer EK, Huper G, Iglehart JD, Marks JR: Inhibition of mitogen-activated protein kinase and phosphatidylinositol 3-kinase activity in MCF-7 cells prevents estrogen-induced mitogenesis. Cell Growth Differ 2000; 11: 99-110.
39. Read LD, Keith D Jr, Slamon DJ, Katzenellenbogen BS: Hormonal modulation of HER-2/Neu protooncogene messenger ribonucleic acid and p185 protein expression in human breast cancer cell lines. Cancer Res 1990; 50: 3947-3951.
40. Bourdeau V, Deschenes J, Metivier R, Nagai Y, Nguyen D, Bretschneider N, Gannon F, White JH, Mader S: Genome-wide identification of high-affinity estrogen response elements in human and mouse. Mol Endocrinol 2004; 18: 1411-1427.
41. Arnold SF, Vorojeikina DP, Notides AC: Phosphorylation of tyrosine 537 on the human estrogen receptor is required for binding to an estrogen response element. J Biol Chem 1995; 270: 30205-30212.
42. Arnold SF, Obourn JD, Jaffe H, Notides AC: Serine 167 is the major estradiol-induced phosphorylation site on the human estrogen receptor. Mol Endocrinol 1994; 8: 1208-1214.
43. Murphy LC, Weitsman GE, Skliris GP, Teh EM, Li L, Peng B, Davie JR, Ung K, Niu YL, Troup S, Tomes L, Watson PH: Potential role of estrogen receptor alpha (ERalpha) phosphorylated at serine118 in human breast cancer in vivo. J Steroid Biochem Mol Biol 2006; 102: 139-146.
44. Antoniotti S, Taverna D, Maggiora P, Sapei ML, Hynes NE, De Bortoli M: Oestrogen and epidermal growth factor down-regulate erbB-2 oncogene protein expression in breast cancer cells by different mechanisms. Br J Cancer 1994; 70: 1095-1101.
45. Song RX, Chen Y, Zhang Z, Bao Y, Yue W, Wang JP, Fan P, Santen RJ: Estrogen utilization of IGF-1-R and EGF-R to signal in breast cancer cells. J Steroid Biochem Mol Biol 2010; 118: 219-230.
46. Castoria G, Barone MV, Di Domenico M, Bilancio A, Ametrano D, Migliaccio A, Auricchio F: Non-transcriptional action of oestradiol and progestin triggers DNA synthesis. Embo J 1999; 18: 2500-2510.
47. Gianni L, Norton L, Wolmark N, Suter TM, Bonadonna G, Hortobagyi GN: Role of anthracyclines in the treatment of early breast cancer. J Clin Oncol 2009; 27: 4798-4808.
48. Hug V, Hortobagyi GN, Drewinko B, Finders M: Tamoxifen-citrate counteracts the antitumor effects of cytotoxic drugs in vitro. J Clin Oncol 1985; 3: 1672-1677.
49. Rivkin SE, Green S, Metch B, Cruz AB, Abeloff MD, Jewell WR, Costanzi JJ, Farrar WB, Minton JP, Osborne CK: Adjuvant CMFVP versus tamoxifen versus concurrent CMFVP and tamoxifen for postmenopausal, nodepositive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group study. J Clin Oncol 1994; 12: 2078-2085.
50. Pritchard KI, Paterson AH, Fine S, Paul NA, Zee B, Shepherd LE, Abu-Zahra H, Ragaz J, Knowling M, Levine MN, Verma S, Perrault D, Walde PL, Bramwell VH, Poljicak M, Boyd N, Warr D, Norris BD, Bowman D, Armitage GR, Weizel H, Buckman RA: Randomized trial of cyclophosphamide, methotrexate, and fluorouracil chemotherapy added to tamoxifen as adjuvant therapy in postmenopausal women with node-positive estrogen and/or progesterone receptor-positive breast cancer: a report of the National Cancer Institute of Canada Clinical Trials group. Breast Cancer Site group. J Clin Oncol 1997; 15: 2302-2311.
51. Early Breast Cancer Trialists' Collaborative Group (EBCTCG): Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365: 1687-1717.
52. de la Haba-Rodriguez J, Mancha RG, Manga GP, Aguilar EA, Baena Canada JM, Rovira PS, Conejo EA: Exemestane and chemotherapy as first-line treatment of metastatic breast cancer: results of a phase II study. Clin Breast Cancer 2010; 10: 313-317.
53. Migliaccio A, Castoria G, Di Domenico M, de Falco A, Bilancio A, Lombardi M, Bottero D, Varricchio L, Nanayakkara M, Rotondi A, Auricchio F: Sex steroid hormones act as growth factors. J Steroid Biochem Mol Biol 2002; 83: 31-35.
54. Chen Y, Alvarez EA, Azzam D, Wander SA, Guggisberg N, Jorda M, Ju Z, Hennessy BT, Slingerland JM: Combined Src and ER blockade impairs human breast cancer proliferation in vitro and in vivo. Breast Cancer Res Treat 2011; 128: 69-78.
55. Crowder RJ, Phommaly C, Tao Y, Hoog J, Luo J, Perou CM, Parker JS, Miller MA, Huntsman DG, Lin L, Snider J, Davies SR, Olson JA Jr, Watson MA, Saporita A, Weber JD, Ellis MJ: PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer. Cancer Res 2009; 69: 3955-3962.
56. Hitosugi T, Sasaki K, Sato M, Suzuki Y, Umezawa Y: Epidermal growth factor directs sex-specific steroid signaling through Src activation. J Biol Chem 2007; 282: 10697-10706.
57. Hewitt SC, Li Y, Li L, Korach KS: Estrogenmediated regulation of IGF1 transcription and uterine growth involves direct binding of estrogen receptor alpha to estrogen-responsive elements. J Biol Chem 2010; 285: 2676-2685.
58. Lee YR, Park J, Yu HN, Kim JS, Youn HJ, Jung SH: Up-regulation of PI3K/Akt signaling by 17beta-estradiol through activation of estrogen receptor-alpha, but not estrogen receptor-beta, and stimulates cell growth in breast cancer cells. Biochem Biophys Res Commun 2005; 336: 1221-1226.
59. Apparao KB, Lovely LP, Gui Y, Lininger RA, Lessey BA: Elevated endometrial androgen receptor expression in women with polycystic ovarian syndrome. Biol Reprod 2002; 66: 297-304.
60. Yarden RI, Wilson MA, Chrysogelos SA: Estrogen suppression of EGFR expression in breast cancer cells: a possible mechanism to modulate growth. J Cell Biochem Suppl 2001;(suppl 36):232-246.
61. Valley CC, Metivier R, Solodin NM, Fowler AM, Mashek MT, Hill L, Alarid ET: Differential regulation of estrogen-inducible proteolysis and transcription by the estrogen receptor alpha N terminus. Mol Cell Biol 2005; 25: 5417-5428.
62. Castellano I, Allia E, Accortanzo V, Vandone AM, Chiusa L, Arisio R, Durando A, Donadio M, Bussolati G, Coates AS, Viale G, Sapino A: Androgen receptor expression is a significant prognostic factor in estrogen receptor positive breast cancers. Breast Cancer Res Treat 2010; 124: 607-617.
63. Okubo S, Kurebayashi J, Otsuki T, Yamamoto Y, Tanaka K, Sonoo H: Additive antitumour effect of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (Iressa, ZD1839) and the antioestrogen fulvestrant (Faslodex, ICI 182,780) in breast cancer cells. Br J Cancer 2004; 90: 236-244.
64. Creighton CJ, Fu X, Hennessy BT, Casa AJ, Zhang Y, Gonzalez-Angulo AM, Lluch A, Gray JW, Brown PH, Hilsenbeck SG, Osborne CK, Mills GB, Lee AV, Schiff R: Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer. Breast Cancer Res 2010; 12:R40.
65. Reddy KB, Glaros S: Inhibition of the MAP kinase activity suppresses estrogen-induced breast tumor growth both in vitro and in vivo. Int J Oncol 2007; 30: 971-975.
66. Creighton CJ, Massarweh S, Huang S, Tsimelzon A, Hilsenbeck SG, Osborne CK, Shou J, Malorni L, Schiff R: Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenografts. Cancer Res 2008; 68: 7493-7501.
67. Untch M, Gelber RD, Jackisch C, Procter M, Baselga J, Bell R, Cameron D, Bari M, Smith I, Leyland-Jones B, de Azambuja E, Wermuth P, Khasanov R, Feng-Yi F, Constantin C, Mayordomo JI, Su CH, Yu SY, Lluch A, Senkus-Konefka E, Price C, Haslbauer F, Suarez Sahui T, Srimuninnimit V, Colleoni M, Coates AS, Piccart-Gebhart MJ, Goldhirsch A: Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial. Ann Oncol 2008; 19: 1090-1096.
68. Regan MM, Gelber RD: Using clinical trial data to tailor adjuvant treatments for individual patients. Breast 2007; 16(suppl 2):S98-S104.
69. Perrault DJ, Logan DM, Stewart DJ, Bramwell VH, Paterson AH, Eisenhauer EA: Phase II study of flutamide in patients with metastatic breast cancer. A National Cancer Institute of Canada Clinical Trials Group study. Invest New Drugs 1988; 6: 207-210.
70. Pichot CS, Hartig SM, Xia L, Arvanitis C, Monisvais D, Lee FY, Frost JA, Corey SJ: Dasatinib synergizes with doxorubicin to block growth, migration, and invasion of breast cancer cells. Br J Cancer 2009; 101: 38-47.
71. Ren W, Korchin B, Zhu QS, Wei C, Dicker A, Heymach J, Lazar A, Pollock RE, Lev D: Epidermal growth factor receptor blockade in combination with conventional chemotherapy inhibits soft tissue sarcoma cell growth in vitro and in vivo. Clin Cancer Res 2008; 14: 2785-2795.
72. Wang YA, Johnson SK, Brown BL, McCarragher LM, Al-Sakkaf K, Royds JA, Dobson PR: Enhanced anti-cancer effect of a phosphatidylinositol-
73. kinase inhibitor and doxorubicin on human breast epithelial cell lines with different p53 and oestrogen receptor status. Int J Cancer 2008; 123: 1536-1544.
74. Campos SM, Berlin ST, Parker LM, Chen WY, Bunnell CA, Atkinson T, Lee J, Matulonis U, Hirsch MS, Harris L, Krasner CN: Phase I trial of liposomal doxorubicin and ZD1839 in patients with refractory gynecological malignancies or metastatic breast cancer. Int J Clin Oncol 2010; 15: 390-398.
75. Patten RD, Pourati I, Aronovitz MJ, Baur J, Celestin F, Chen X, Michael A, Haq S, Nuedling S, Grohe C, Force T, Mendelsohn ME, Karas RH: 17beta-estradiol reduces cardiomyocyte apoptosis in vivo and in vitro via activation of phospho-inositide-3 kinase/ Akt signaling. Circ Res 2004; 95: 692-699.
76. Mitsiades N, Yu WH, Poulaki V, Tsokos M, Stamenkovic I: Matrix metalloproteinase-7-mediated cleavage of FAS ligand protects tumor cells from chemotherapeutic drug cytotoxicity. Cancer Res 2001; 61: 577-581.
77. Wetzel M, Rosenberg GA, Cunningham LA: Tissue inhibitor of metalloproteinases-3 and matrix metalloproteinase-3 regulate neuronal sensitivity to doxorubicin-induced apoptosis. Eur J Neurosci 2003; 18: 1050-1060.
78. Nilsson UW, Garvin S, Dabrosin C: MMP-2 and MMP-9 activity is regulated by estradiol and tamoxifen in cultured human breast cancer cells. Breast Cancer Res Treat 2007; 102: 253-261.
79. Philips N, McFadden K: Inhibition of transforming growth factor-beta and matrix metalloproteinases by estrogen and prolactin in breast cancer cells. Cancer Lett 2004; 206: 63-68.
80. Zhao Y, Shen S, Guo J, Chen H, Greenblatt DY, Kleeff J, Liao Q, Chen G, Friess H, Leung PS: Mitogen-activated protein kinases and chemoresistance in pancreatic cancer cells. J Surg Res 2006; 136: 325-335.
81. Choi J, Yip-Schneider M, Albertin F, Wiesenauer C, Wang Y, Schmidt CM: The effect of doxorubicin on MEK-ERK signaling predicts its efficacy in HCC. J Surg Res 2008; 150: 219-226.
82. Brantley-Finley C, Lyle CS, Du L, Goodwin ME, Hall T, Szwedo D, Kaushal GP, Chambers TC: The JNK, ERK and p53 pathways play distinct roles in apoptosis mediated by the antitumor agents vinblastine, doxorubicin, and etoposide. Biochem Pharmacol 2003; 66: 459-469.
83. Waller AS, Sharrard RM, Berthon P, Maitland NJ: Androgen receptor localisation and turnover in human prostate epithelium treated with the antiandrogen, casodex. J Mol Endocrinol 2000; 24: 339-351.
84. Masiello D, Cheng S, Bubley GJ, Lu ML, Balk SP: Bicalutamide functions as an androgen receptor antagonist by assembly of a transcriptionally inactive receptor. J Biol Chem 2002; 277: 26321-26326.
85. NCI: Clinical trials database. National Cancer Institute, 2011.
86. Buzdar AU: Role of biologic therapy and chemotherapy in hormone receptor-and HER2-positive breast cancer. Ann Oncol 2009; 20: 993-999.
87. Reuter CW, Catling AD, Weber MJ: Immune complex kinase assays for mitogen-activated protein kinase and MEK. Methods Enzymol 1995; 255: 245-256.